Core Viewpoint - The rapid development of artificial intelligence and biomedicine is leading to unprecedented changes in the healthcare service industry [2][6]. IPO Details - Zhuozheng Medical Holdings Limited is set to be listed on the Hong Kong Stock Exchange on February 6, 2026, under the stock code "2677" [2]. - The company issued a total of 4,750,000 shares, raising a total of HKD 284 million, with a subscription rate of 2730.73 times for the public offering and 5.79 times for the international offering [2]. - Notable cornerstone investors include He Xiaopeng, CEO of Xiaopeng Motors, who subscribed for USD 1 million, and other tech companies with AI attributes [3]. Market Position and Growth - Zhuozheng Medical ranks first and second among private high-end comprehensive medical service institutions in terms of the number of cities covered and the number of paid patient visits in 2024 [9]. - The company has a strong reputation based on service quality, with high net promoter scores (NPS) of 81.1, 86.4, 85.9, and 87.6 from 2022 to 2025 [9]. Membership and Customer Retention - As of August 31, 2025, Zhuozheng Medical had 116,542 member accounts, with renewal rates increasing from 42% in 2022 to 67% in 2025 [11]. - The patient return rate also improved from 75.7% in 2022 to 82.7% in 2025, indicating strong customer loyalty [11]. Business Model - Zhuozheng Medical adopts a Costco-like model in the healthcare sector, focusing on a membership system and high-value services to drive growth [11][13]. - The company offers a range of services that cater to high-frequency health needs, allowing for longer customer retention periods and higher consumption frequency [13]. Financial Performance - Zhuozheng Medical achieved revenue growth from CNY 473 million in 2022 to CNY 959 million in 2024, with a compound annual growth rate (CAGR) of 42.2% [14]. - The gross profit also increased significantly, from CNY 44 million in 2022 to CNY 226 million in 2024, with a CAGR of 126.7% [14]. - The company turned profitable in 2024, with an adjusted net profit of approximately CNY 10.45 million in the first eight months of 2025 [14]. Investor Support - Zhuozheng Medical has received investments from notable firms such as Tencent, Matrix Partners, Tiantu Capital, and others, indicating strong institutional support [16][17]. - Investors believe that the company is well-positioned to meet the growing demand for high-quality healthcare services in China [17][18].

Core Viewpoint - Zhuozheng Medical, a leading company in the domestic health consumption industry, is set to launch its IPO from January 29 to February 3, 2026, with a global offering of 4.75 million shares priced between HKD 57.7 and HKD 66.6 [1] Group 1: Financial Performance - Zhuozheng Medical has achieved continuous revenue and profit growth despite challenges in the medical service industry, with revenues projected at RMB 470 million, RMB 690 million, and RMB 960 million from 2022 to 2024, reflecting a compound annual growth rate (CAGR) of 42.2% [2] - The company's gross profit has also increased significantly, with figures of RMB 43.98 million, RMB 130 million, and RMB 230 million over the same period, resulting in a CAGR of 126.7% [2] - Zhuozheng Medical turned profitable in 2024, with adjusted net profits of RMB -123 million, RMB -43.57 million, and RMB 10.7 million over the last three years, and an adjusted net profit of RMB 10.45 million in the first eight months of 2025 [2] - The net cash flow from operating activities has shown steady growth, with amounts of RMB 6.86 million, RMB 12.4 million, and RMB 17.1 million in the last three years, reaching RMB 11.2 million in the first eight months of 2025 [2] Group 2: Business Model - Zhuozheng Medical's revenue model is distinct, with over 85% of its income coming from cash payments and approximately 12% from commercial insurance, while income from national medical insurance is minimal [4] - The company has low marketing costs, with marketing expenses accounting for only 2.7%, 1.2%, and 1.7% of revenue from 2022 to 2024, primarily for brand personnel salaries rather than sales [4] - High customer retention is achieved through excellent customer reputation, with membership renewal rates of approximately 42%, 56%, 64%, and 67% from 2022 to 2025, and patient return rates of 75.7%, 78.2%, 80.0%, and 82.7% over the same period [5] Group 3: Growth Strategy - Zhuozheng Medical employs a business model similar to Costco, focusing on high-frequency health services and a family membership plan that encourages multiple visits across various specialties [7][8] - The company targets high-frequency health needs rather than low-frequency severe illnesses, extending customer engagement through a comprehensive service offering [7] - In 2024, Zhuozheng Medical served approximately 240,000 customers with around 900,000 visits, averaging nearly four visits per customer, significantly higher than traditional single-specialty medical institutions [8] Group 4: Investment and Market Position - Zhuozheng Medical has attracted significant investment interest, with notable shareholders including Tencent, which holds nearly 20% of the company, and other prominent investment firms [11] - The company has garnered attention from cornerstone investors, including leading firms in third-party testing and the electric vehicle sector, indicating strong market confidence in its business model and growth potential [11] - The backing from various Tencent-affiliated companies aligns with Zhuozheng Medical's AI transformation strategy, enhancing collaborative opportunities for future growth [11]